CA2483464A1 - Method for treating obesity - Google Patents

Method for treating obesity Download PDF

Info

Publication number
CA2483464A1
CA2483464A1 CA002483464A CA2483464A CA2483464A1 CA 2483464 A1 CA2483464 A1 CA 2483464A1 CA 002483464 A CA002483464 A CA 002483464A CA 2483464 A CA2483464 A CA 2483464A CA 2483464 A1 CA2483464 A1 CA 2483464A1
Authority
CA
Canada
Prior art keywords
compound
anticonvulsant
norepinephrine
enhances
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002483464A
Other languages
French (fr)
Other versions
CA2483464C (en
Inventor
Kishore M. Gadde
K. Ranga R. Krishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2483464A1 publication Critical patent/CA2483464A1/en
Application granted granted Critical
Publication of CA2483464C publication Critical patent/CA2483464C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claims (17)

1. A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one weight-loss promoting anticonvulsant and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said treatment is effected.
2. The method according to claim 1 wherein said anticonvulsant is of the formula (I):
wherein X is CH2 or oxygen, R1 is hydrogen or alkyl, R2, R3, R4 and R5 are independently hydrogen or lower alkyl, and when X is CH2, R4 and R5 can be alkene groups joined to form a benzene ring and when X is oxygen, R2 and R3 and/or R4 and R5 together can be a methylenedioxy group of the following formula (II):
wherein R6 and R7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
3. The method according to claim 2 wherein R1 is hydrogen or a C1-C4 alkyl, straight and branched chain, and R2, R3, R4, R5, R6 and R7 are a C1-C3 alkyl, straight or branched chain.
4. The method according to claim 1 wherein said anticonvulsant is of the formula (III):
wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group -CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
5. The method according to claim 1 wherein said anticonvulsant is zonisamide or topiramate.
6. The method according to claim 1 wherein said compound that enhances the activity of norepinephrine and/or dopamine effects said enhancement via uptake inhibition.
7. The method according to claim 1 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion, Atomoxetine or Reboxetine.
8. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.
9. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.
10. A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction at least one weight-loss promoting anticonvulsant and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said reduction is effected.
11. A method of treating obesity in mammal comprising administering to a mammal in need of such treatment a compound of formula (III):
wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group -CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof, in an amount sufficient to effect said treatment.
12. The method according to claim 11 wherein said compound is zonisamide.
13. A composition comprising at least one weight loss-promoting anticonvulsant and at least one compound that enhances the activity of norepinephrine and/or dopamine.
14. The composition according to claim 13 wherein said compound is in dosage unit form.
15. The composition according to claim 14 wherein said composition is in the form of a tablet or capsule.
16. The composition according to claim 13 wherein said anticonvulsant is zonisamide or topiramate.
17. The composition according to claim 13 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.
CA2483464A 2002-05-17 2003-05-19 Method for treating obesity Expired - Lifetime CA2483464C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38087402P 2002-05-17 2002-05-17
US60/380,874 2002-05-17
PCT/US2003/015703 WO2003097046A1 (en) 2002-05-17 2003-05-19 Method for treating obesity

Publications (2)

Publication Number Publication Date
CA2483464A1 true CA2483464A1 (en) 2003-11-27
CA2483464C CA2483464C (en) 2011-12-20

Family

ID=29550030

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2483464A Expired - Lifetime CA2483464C (en) 2002-05-17 2003-05-19 Method for treating obesity

Country Status (11)

Country Link
US (7) US7109198B2 (en)
EP (3) EP1505967B1 (en)
JP (1) JP4545584B2 (en)
KR (2) KR101072885B1 (en)
CN (1) CN1320886C (en)
AU (1) AU2003231788B2 (en)
CA (1) CA2483464C (en)
HK (1) HK1074778A1 (en)
MX (1) MXPA04011203A (en)
RU (1) RU2341259C2 (en)
WO (1) WO2003097046A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20190290618A1 (en) * 2002-05-17 2019-09-26 Duke University Method for Treating Obesity
KR101072885B1 (en) * 2002-05-17 2011-10-17 듀크 유니버시티 Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20190262318A1 (en) * 2002-05-17 2019-08-29 Duke University Method for Treating Obesity
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
KR101167579B1 (en) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. Compositions for affecting weight loss
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (en) 2004-01-13 2007-05-29 Univ Duke Anticonvulsant and antipsychotic drug compositions and methods for their use to affect weight loss
SE0400378D0 (en) * 2004-02-17 2004-02-17 Jan Hedner Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
RU2006139930A (en) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) COMPOSITIONS FOR PROMOTING WEIGHT LOSS
US20060153934A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and magnesium
RU2007142346A (en) * 2005-05-31 2009-07-20 Ориксиджен Серапьютикс, Инкорпорэйтд (Сша/Сша) (Us) METHODS AND COMPOSITIONS FOR THE CONTROL OF PSYCHOTIC DISORDERS
JP5095615B2 (en) * 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ Modified release of bupropion salt
BRPI0615211A2 (en) 2005-08-17 2013-01-15 Hills Pet Nutrition Inc method, method for preventing or treating renal disease or improving renal function, kit, and means for communicating information on or instructions for mixing and administering one or more of the compositions, composition components, food compositions, food ingredients and renal medicines and for the use of renal diagnostic devices
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
WO2007047351A2 (en) * 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
ES2761812T3 (en) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composition and methods of increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517394A (en) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド Sustained release formulation of zonisamide
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
TWI504419B (en) 2006-11-09 2015-10-21 Orexigen Therapeutics Inc Layered pharmaceutical formulations
KR20140088619A (en) * 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. Unit dosage packages
EP2303025A4 (en) * 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Methods for treating visceral fat conditions
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
WO2009152152A1 (en) * 2008-06-09 2009-12-17 Amarillo Biosciences, Inc. Treatment of obesity with an interferon
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8114445B2 (en) * 2008-11-07 2012-02-14 Reliv International Inc. Dietary supplement for promoting wellness and weight loss and methods of administering the same
JP2012513764A (en) * 2008-12-30 2012-06-21 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Compositions and methods for treating and preventing weight related disorders in companion animals
EP2515656B1 (en) * 2009-12-21 2014-08-06 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
CN102724878A (en) 2010-01-11 2012-10-10 奥雷西根治疗公司 Methods of providing weight loss therapy in patients with major depression
US8440655B2 (en) 2010-06-21 2013-05-14 Theracos, Inc. Combination therapy for the treatment of diabetes
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
WO2013012760A1 (en) 2011-07-15 2013-01-24 Numeta Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
DK3730132T3 (en) 2012-06-06 2022-08-08 Nalpropion Pharmaceuticals Llc COMPOSITION FOR USE IN A METHOD FOR TREATING OVERWEIGHT AND OBESITY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK
CN104918610B (en) 2012-11-13 2018-04-10 纽斯尔特科学公司 For strengthening the composition and method of energetic supersession
JP2016505023A (en) 2013-01-15 2016-02-18 ニューサート サイエンシーズ， インコーポレイテッド Treatment of lung conditions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
RU2015143836A (en) 2013-03-15 2017-04-27 Нусерт Сайенсиз, Инк. Leucine and Niacin to Reduce Lipid Levels
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
KR20160119863A (en) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. Compositions and methods for the reduction or prevention of hepatic steatosis
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US122033A (en) * 1871-12-19 Improvement in rotary engines
US106576A (en) * 1870-08-23 Improvement in washing-machines
US143322A (en) * 1873-09-30 blake
US100205A (en) * 1870-02-22 Improvement in furnaces
US277579A (en) * 1883-05-15 Axle-skein
US144174A (en) * 1873-10-28 Improvement in steam-engine valve-gears
US2462A (en) * 1842-02-21 Worked buttons on the heads
US79501A (en) * 1868-06-30 Jambs righey
US9514A (en) * 1853-01-04 Improvement in self-winding telegraphic registers
US137144A (en) * 1873-03-25 Improvement in stop-cocks
US154002A (en) * 1874-08-11 Improvement in electric telegraphs
US160750A (en) * 1875-03-16 Improvement in grain-separators
US58293A (en) * 1866-09-25 Improved lady s-saddle tree
US33965A (en) * 1861-12-17 Improvement in rifle-sights
US55008A (en) * 1866-05-22 Improved clothes-sprinkler
US181070A (en) * 1876-08-15 Improvement in burglar-proof gratings
US215552A (en) * 1879-05-20 Improvement in gar-couplings
US142290A (en) * 1873-08-26 Improvement in trimming attachments for sewing-machines
US254208A (en) * 1882-02-28 Geoegb e
US26986A (en) * 1860-01-31 Mortising-machine
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (en) 1969-12-04 1971-06-03 Wellcome Found KETONES WITH BIOLOGICAL ACTIVITY
US4089855A (en) * 1976-04-23 1978-05-16 Cornell Research Foundation, Inc. Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4689332A (en) * 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
NL8800823A (en) * 1987-04-10 1988-11-01 Sandoz Ag METHOD FOR USING DOPAMINE RECEPTOR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE AGONISTS
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
WO1990013294A1 (en) 1989-05-09 1990-11-15 Whitby Research, Inc. A method of reducing body weight and food intake using a dopamine d2 receptor agonist
FR2657350B1 (en) 1990-01-19 1992-05-15 Centre Nat Rech Scient COMPOUNDS FOR ENCAPSULATION IN ERYTHROCYTES - NEW DERIVATIVES OF NALOXONE AND NALTREXONE.
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
EP0782445B1 (en) 1994-09-19 2002-03-13 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5713488A (en) * 1996-01-24 1998-02-03 Farrugia; John V. Condom dispenser
JPH11505547A (en) * 1996-03-13 1999-05-21 エール ユニバーシティ Smoking cessation treatment with naltrexone and related compounds
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
UA53655C2 (en) 1996-06-28 2003-02-17 Орто-Макнейл Фармасьютікел, Інк. Method for treating obesity
FR2758723B1 (en) * 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
DE69811378T2 (en) * 1997-10-03 2004-02-12 Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) COMPOSITIONS FOR TREATING NICOTINE DEPENDENCY, CONTAINING MECAMYLAMINE AND BUPROPION
US6262049B1 (en) * 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Pharmaceutical compositions containing piperazinyl-heterocyclic compounds for treating psychiatric disorders
DE69830512T2 (en) * 1997-12-26 2006-03-23 Dainippon Pharmaceutical Co., Ltd. Drug for neurodegenerative diseases
BR9907203A (en) 1998-01-21 2000-10-17 Glaxo Group Ltd "compound, pharmaceutical compositions, use of a compound, and, depression treatment process, attention deficit hyperactivity disorder (adhd), obesity, migraine, pain, sexual dysfunction, parkinson's disease, alzeheimer disease, or addiction to cocaine or nicotine-containing products (especially tobacco) in an animal or human individual. "
JP2002501892A (en) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド Pharmaceutical use of optically pure (-)-viewpropion
US6048322A (en) * 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
HUP0200469A3 (en) * 1999-02-24 2003-03-28 Univ Cincinnati Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6267995B1 (en) 1999-03-03 2001-07-31 Pure World Botanicals, Inc. Extract of Lepidium meyenii roots for pharmaceutical applications
CN1329359C (en) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 Ether compounds, compositions, and uses thereof
CZ20013607A3 (en) 1999-04-06 2002-06-12 Sepracor Inc. Pharmaceutical preparation
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
EP2308481B1 (en) 1999-06-14 2015-05-06 Vivus, Inc. Combination therapy for the treatment of hypertension associated with obesity
PT1459750E (en) * 1999-07-01 2005-08-31 Pharmacia & Upjohn Co Llc (S, S) - REBOXETINE FOR TREATING FIBROMYALGIA OR OTHER SOMATOFORM PERTURBACTIONS
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
US20030144271A1 (en) * 2000-01-22 2003-07-31 Albert Shulman Methods for the treatment of substance abuse
US20020090615A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1263438B1 (en) * 2000-03-15 2006-05-17 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US6437147B1 (en) * 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6627653B2 (en) * 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
EP1326630B1 (en) * 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
JP2004518718A (en) * 2000-10-30 2004-06-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Combination therapy comprising antidiabetic and anticonvulsants
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US6481031B1 (en) * 2001-11-14 2002-11-19 In Mo Hwang Pillow oriented for comfort in varying sleeping positions
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
KR101072885B1 (en) * 2002-05-17 2011-10-17 듀크 유니버시티 Method for treating obesity
US20050215552A1 (en) 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP1534074A4 (en) 2002-07-18 2008-01-09 Merck & Co Inc Combination therapy for the treatment of obesity
JP2006507251A (en) 2002-09-13 2006-03-02 エーザイ株式会社 How to treat tremor
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
KR101167579B1 (en) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. Compositions for affecting weight loss
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
EP1635773A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
KR100965580B1 (en) * 2003-08-21 2010-06-23 엘지디스플레이 주식회사 Liquid crystal display apparatus and driving method thereof
WO2005049043A1 (en) 2003-11-18 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising metformin and anticonvulsant agents
US20060160750A1 (en) 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
BRPI0506829A (en) 2004-01-13 2007-05-29 Univ Duke Anticonvulsant and antipsychotic drug compositions and methods for their use to affect weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005107806A1 (en) 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
RU2006139930A (en) 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) COMPOSITIONS FOR PROMOTING WEIGHT LOSS
RU2007103313A (en) 2004-08-03 2008-09-10 ОРЕКСИДЖЕН ТЕРАПЬЮТИКС, ИНК. (Канада/США) (US) COMBINATION OF BUPROPINE AND OTHER COMPOSITION FOR EFFECTIVE WEIGHT LOSS
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
US7346233B2 (en) * 2005-02-14 2008-03-18 Corning Incorporated Single mode (SM) fiber optical reader system and method for interrogating resonant waveguide-grating sensor(s)

Also Published As

Publication number Publication date
CN1320886C (en) 2007-06-13
RU2004131636A (en) 2005-06-27
EP2301537A1 (en) 2011-03-30
US7109198B2 (en) 2006-09-19
US20040198668A1 (en) 2004-10-07
US20040033965A1 (en) 2004-02-19
MXPA04011203A (en) 2005-07-14
US20080319036A1 (en) 2008-12-25
US7425571B2 (en) 2008-09-16
JP2005530782A (en) 2005-10-13
KR20050023265A (en) 2005-03-09
RU2341259C2 (en) 2008-12-20
US20060009514A1 (en) 2006-01-12
US20050137144A1 (en) 2005-06-23
EP1505967B1 (en) 2016-07-13
KR101072885B1 (en) 2011-10-17
US20050143322A1 (en) 2005-06-30
US7754748B2 (en) 2010-07-13
HK1074778A1 (en) 2005-11-25
EP1505967A1 (en) 2005-02-16
AU2003231788A1 (en) 2003-12-02
JP4545584B2 (en) 2010-09-15
US20080188476A1 (en) 2008-08-07
CA2483464C (en) 2011-12-20
EP1505967A4 (en) 2007-09-05
EP3173082A1 (en) 2017-05-31
KR20110043664A (en) 2011-04-27
AU2003231788B2 (en) 2008-09-11
CN1652778A (en) 2005-08-10
WO2003097046A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
CA2483464A1 (en) Method for treating obesity
CA2377330A1 (en) Combination therapy for effecting weight loss and treating obesity
JP2004524312A5 (en)
EP2335734A3 (en) Treatment of pain and other alpha 2 adrenergic-mediated conditions
RU2003100076A (en) ANTI-CURRENT DERIVATIVES USED TO PREVENT DEVELOPMENT OF DIABETES AND SYNDROME X
MY157828A (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
CA2430692A1 (en) Geldanamycin derivative and use of same to treat cancer
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
TW200621233A (en) HCV NS3-NS4A protease inhibition
SG149814A1 (en) Compositions and methods for treating diabetes
MXPA04001643A (en) (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor.
CA2439838A1 (en) (2-hydroxy)ethyl-thioureas useful as modulators of alpha2b adrenergic receptors
CA2617817A1 (en) Thiazole derivatives for treating or preventing sleep disorders
MX2012000488A (en) Combination therapy for the treatment of diabetes.
RU2008133654A (en) METHOD AND MEDICINE FOR TREATMENT OF SEVERE HEART FAILURE
CO5200778A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A THERAPEUTICALLY EFFECTIVE AMOUNT OF B ENZIMIDAZOL, ADMINISTERED TO PREVENT AND TREAT CANCER AND INHIBIT METASTASIS
DE60238391D1 (en) AZOLE AS MALONYL-COA DECARBOXYLASE HEMMER USES AS MODULATORS OF METABOLISM
RU2002133868A (en) CANNABINOID MEDICINES
CA2620065A1 (en) Methods and formulations for modulating lyn kinase activity and treating related disorders
JP2005512965A5 (en)
FI3164125T3 (en) Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes
CA2525373A1 (en) Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
JP2004525905A5 (en)
EA200600626A1 (en) COMPOSITION AND MEDICATION FORM OF LOW DUCTED LONGIODOPA
HRP20080255A2 (en) Use of cicletanine and other furopyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230519